Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Umbrella Trial Based on Molecular Pathway for Patients With Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer (FUTURE SUPER)

Next Previous
Trial Profile

An Umbrella Trial Based on Molecular Pathway for Patients With Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer (FUTURE SUPER)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Camrelizumab (Primary) ; Capecitabine (Primary) ; Everolimus (Primary) ; Famitinib (Primary) ; Paclitaxel (Primary) ; Pyrotinib (Primary)
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms FUTURE SUPER

Most Recent Events

  • 08 Jan 2024 Primary endpoint has been met. (investigator-assessed progression-free survival for the pooled subtyping-based group versus the control group in the intention-to-treat population (all randomly assigned participants), as per published in the Lancet Oncology
  • 08 Jan 2024 Results evaluating the efficacy and safety of subtyping-based therapy in the first-line treatment of triple-negative breast cancer, published in the Lancet Oncology
  • 17 Dec 2023 Planned End Date changed from 15 Nov 2023 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top